2Gaylen A.Uhlich,James E.Keen,and Roert O.Eldert,Variations in the csaD Promoter of Escherichia coliO157:H7 Associated with Increased Virulence in mice and Increased Invasion of HEp-2 Cells[J].Infection and Immunity.Jan.2002,395-399.
3Wadolkowski,E.A.,J.A.Burris,and A.D.O'Brien.1990 Mouse model for colonization and disease caused by enterobemorrhagic Escherichia coli O157:H7[J].Infect.Immun.58:2438-2445.
4Isoga E,Isoga,Hayashi S,et al.Effect of antibiotics,levofloxacin and fosfomycin on a mouse model with Escherichia coli O157:H7 infection[J].Microbiol Immunol,2000,44(2):89-95.
5Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med, 1983, 308: 681-685.
6Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157 infections. Pediatrics, 1997, 100(1): E12.
8Fitzhenry RJ, Pickard DJ, Hartland EL, et al. Intimin type influences the site of human intestinal mucosal colonization by enterohaemorrhagic Escherichia coli O157:H7. Gut, 2002, 50(2): 180-185.
9Son WG, Graham TA, Gannon VPJ, et al. Immunological characterization of Escherichia coli O157:H7 intimin gamma1. Clin Diagn Lab Immunol, 2002, 9(1): 46-53.
10Dean NEA, Gansheroff LJ, Mills M, et al. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun, 2002, 70(5): 2414-2418.
2U.S.Department of Health & Human Services, FDA office of Women ' s Health and CBER : Workshop on non - clinical safety evaluation of preventive vaccines: Recent advances and regulatory considerations [ EB/OL ] . http ://www. fda. gov/cber/minutes/ tox120302.htm.2002-12 03.2008 05 08.
3WHO. Guidelines on preclinical evaluation of vaccine ( Draft ) . [ EB/OL ] . http ://www. pasteur, fr/recherche/Cry/Documents/WHO Nonclinical evaluation vaccines. Nov 2003.pdf.2003-11-17.2008-05- 08.
4EMEA. Note for guidance on pneclillical pharmacological and toxicologica l test ing of vaccines [ EB/OL ] http ://www. emea. eapa. eu/pdfs/human/swp/046595. pdf.1997-12-17. 2008- 05-08.
5Konadu EY, Parke JC Jr, Tran HT, et al . Investigational vaccine for Escherichia coli O157 : phase I study of O157 O specific polysaccharide l'seudomanas aeruginosa recombinant exoprotein A conjugates in adults[J ] .J Infect Dis, 1998,177(2) :383.
